Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Dimopoulos MA., et al.
November 2020
Authors and Affiliates
Meletios A Dimopoulos 1, Sara Bringhen 2, Pekka M Anttila 3, Marcelo Capra 4, Michele Cavo 5, Craig Emmitt Cole 6, Cristina Gasparetto 7, Vania Tietsche de Moraes Hungria 8, Matthew W Jenner 9, Vladimir I Vorobyev 10, Eduardo Patricio Yanez Ruiz 11, Jian Y Yin 12, Rao Saleem 12, Maeva Hellet 13, Sandrine Macé 14, Bruno Paiva 15, Ravi Vij 16; 1 National and Kapodistrian University of Athens, Athens, Greece. 2 University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. 3 Helsinki University and Helsinki University Hospital, Helksinki, Finland. 4 Hospital Mãe de Deus, Porto Alegre, Brazil. 5 Seràgnoli Institute of Hematology, Bologna, Italy. 6 Michigan State University, East Lansing, Michigan, United States. 7 Duke University. 8 Clinica Sao Germano, São Paulo, Brazil. 9 University Hospital Southampton, Southampton, United Kingdom. 10 S.P. Botkin Hospital, Moscow, Russian Federation. 11 Universidad de la Frontera, Temuco, Chile. 12 Sanofi, Bridgewater, New Jersey, United States. 13 Ividata (for Sanofi), Paris, France. 14 Sanofi, Paris, France. 15 Clinica Universidad de Navarra, Pamplona, Spain. 16 Washington University, St Louis, Missouri, United States.